Clinical Trials

Enrolling Trials

1-10  of  145
4941L, National Wilms Tumor Late Effects Study
McManus, Michael J
Late Effects - Wilms
Child
The objectives of the study are to determine the incidence of life-threatening medical conditions in survivors of Wilms tumor, specifically a) congestive heart failure; b) second malignant neoplasms (SMNs); c) renal failure, and d) pulmonary fibrosis and interstitial lung disease. To relate the risks of these events to the type and amount of radiation and chemotherapy received. To determine mortality rates in former Wilms tumor patients and to compare these with age, calendar period, and sex-specific national population rates. To determine the risks of serious pregnancy complications and other adverse reproductive events in survivors of Wilms tumor, and to correlate their occurrence with the type and amount of radiation and chemotherapy received in childhood. To determine the rates and natality in former Wilms tumor patients and to compare these with national statistics and determne congenital anomalies in offspring. To determine the frequency of Wilms tumor and other cancers in the children and other family members of Wilms tumor patients. Specifically, a) to estimate the recurrence risk in siblings and offspring; and b) to identify familial cancer syndromes that may involve Wilms tumor patients. To serve as a case-finding resource, identifying the most informative subgroups ofWilms tumor patients for use by a) molecular biologists studying mutations in identified or prospective Wilms tumor genes including genes fomilial Wilms tumor; and b) epidemiologists studying parental occupational exposures and other environmental risk factors.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subject 2-17 Years of Age
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Child
This study sponsored by MedImmune aims to assess the effectiveness of the quadrivalent live-attenuated influenza vaccine (QLAIV) in children 2-17 years old when compared to the standard trivalent inactivated influenza vaccine (TIV) and to receiving no vaccine at all. The study will enroll children 2-17 years old with febrile acute respiratory illness who seek care in outpatient settings during influenza seasons starting in fall 2013 and ending after the 2017 influenza season. The vaccine was licensed by the FDA based on studies showing the vaccine generates adequate antibody levels.
Strey, Sandra K
(715) 389-4030
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Chow, Brian
Infectious Disease - Other
Child
MEDI8897 is an experimental medications used to protect infants against Respiratory Syncytial Virus (RSV), which causes viral bronchiolitis and pneumonia. This is a major cause of hospitalization in children. It is expected that one dose of MEDI8897 can be given one to provide protection against RSV for the entire 5 months of RSV season. This study is being carried out to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a substance that looks like the study drug but it does not contain active ingredient.). The study will also measure medication levels of MEDI8897 at different dosages.
Johnson, Tara L
(715) 389-3509
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Hall, Matthew C
Infectious Disease - Other
Adult
This study is to evaluate the antiviral effect, pharmacokinetics, safety, and tolerability of presatovir in respiratory syncytial virus (RSV) positive adults who have been hospitalized with acute respiratory infectious symptoms. Participants will receive 1 dose of presatovir and followed for 28 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.
Freeman, Sandra K
(715) 387-9059
St. Josephs Hospital - Marshfield
611 Saint Joseph Ave
Marshfield, WI  54449
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Anderson, Kelley P
Cardiology
Adult
This study will evaluate the effect of eleclazine on shortening of the corrected QT interval (QTc), safety, and tolerability in adults with type 3 long QT syndrome (LQT3). During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension phase.
Larson, Lisa D
(715) 389-5738
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients.
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Adult
The goal of this study is to learn more about how well people's bodies tolerate a dose of the RSV vaccine, to study the immune response to RSV vaccine in older adults, to find out how often people 60 years old and older get illnesses caused by respiratory viruses over a winter season, whether RSV vaccine has an effect that can be measured, and to find out how well flu shots and the RSV vaccine cause antibodies to be made when they are given together, as compared to when each is given alone. This information will help scientists to know more about the burden of illness caused by respiratory viruses and in developing a widely available vaccine to prevent RSV illness.
Strey, Sandra K
(715) 389-4030
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI  54449
A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Fagbemi, Seth O
Skin
Adult
This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B is more effective than pembrolizumab in treating patients with melanoma.
Strand, Arika P
(715) 389-7543
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Evans, Anthony C, Jr.
Ovaries, Uterus, Cervix - Female Reproductive System Neoplasm, Miscellaneous
Adult
This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid
McManus, Michael J
Blood - Other
Child
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by stopping them from spreading. Completely removing or reducing the amount of anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an effective treatment for acute promyelocytic leukemia and may reduce some of the long-term side effects.
Carpenter, Bonnie M
(715) 389-3639
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Naqvi, Sm Bilal H
Lung - Lung
Adult
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether afatinib dimaleate is more effective when given alone or with cetuximab in treating patients with non-small cell lung cancer.
Bulgrin, Angela M
(715) 221-7261
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494